Research
Hormonal
46 to 75% of participants receiving orforglipron achieved a weight reduction of at least 10% by week 36.
A significant proportion of adults with obesity may achieve clinically meaningful weight loss with orforglipron.
StrongSupportsmedium confidence
A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo.
Why this rating
Based on the phase 2 randomized, double-blind trial design.
Source
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton et al. · New England Journal of Medicine · 2023
rct · n=272Cited 412×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →